DUPIXENT + SOC
200 mg Q2Wa (n=150)
Placebo + SOC (n=158)
DUPIXENT + SOC
300 mg Q2Wb (n=157)
Placebo + SOC (n=158)
DUPIXENT + SOC
200 mg Q2Wa (n=150)
Placebo + SOC (n=158)
DUPIXENT + SOC
300 mg Q2Wb (n=157)
Placebo + SOC (n=158)
Mean change from baseline to Week 12 in FEV1 in patients with baseline eosinophils ≥300 cells/μL
Annualized rate of severe exacerbation events during the 24-week treatment periodc
DUPIXENT + SOC
200 mg Q2Wa (n=631)
Placebo + SOC (n=317)
DUPIXENT + SOC
300 mg Q2Wb (n=633)
Placebo + SOC (n=321)
Annualized rate of severe exacerbation events during the 52-week treatment period in the overall population
Mean change from baseline to Week 12 in FEV1 in the overall population
Annualized rate of severe exacerbation events during the 52-week treatment period in patients with different baseline levels of eosinophils
Annualized rate of severe exacerbation events during the 52-week treatment period in subgroups of patients with ≥1, ≥2, ≥3, or ≥4 exacerbations in the prior year
Mean change from baseline to Week 52 in FEV1 in patients with different baseline levels of eosinophils
Responder rates in patient-reported ACQ-5 and AQLQ(S) scores
DUPIXENT + SOC + OCS
300 mg Q2Wb (n=103)
Placebo + SOC + OCS (n=107)
Annualized rate of severe exacerbation events during the 24-week treatment period
Mean change from baseline to Week 24 in FEV1
Q2W, once every 2 weeks.
Reference: